Literature DB >> 18761602

Impact of telomerase status on canine osteosarcoma patients.

K Kow1, D H Thamm, J Terry, K Grunerud, S M Bailey, S J Withrow, S E Lana.   

Abstract

BACKGROUND: We demonstrated previously that canine osteosarcoma (OSA) cell lines and samples from clinical patients are predominantly telomerase positive. In contrast, the majority of OSA samples from human patients appear to be telomerase negative, maintaining telomere length by an alternative lengthening of telomeres (ALT) mechanism. The purpose of the current study was to examine the telomerase status of a large number of OSA samples from dogs and determine if telomerase status can serve as a prognostic factor. HYPOTHESIS: The majority of clinical canine OSA appendicular lesions will be telomerase positive, and telomerase positivity will negatively impact disease outcome. ANIMALS: Sixty-seven dogs with appendicular OSA presenting to the Colorado State University Animal Cancer Center for treatment.
METHODS: The Telomeric Repeat Amplification Protocol was performed on tissue samples from primary canine appendicular OSA to determine the presence of telomerase activity. Telomere restriction fragment (TRF) analysis was utilized to determine telomere length and detect ALT. Outcome data were obtained in a retrospective manner and correlated with telomerase status.
RESULTS: Seventy-three percent of canine OSA samples were telomerase positive. Telomerase status did not have an impact on disease-free interval or survival time. Nine of 10 telomerase-negative samples examined were consistent with an ALT phenotype, based on TRF analysis. CONCLUSIONS AND CLINICAL IMPORTANCE: These results are consistent with the hypothesis that the majority of canine OSA are telomerase positive, suggesting that telomerase may be a valuable target for canine OSA therapy. Additionally, telomerase status does not appear to be a prognostic factor in canine OSA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761602     DOI: 10.1111/j.1939-1676.2008.0175.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  6 in total

1.  Osteosarcoma tissues and cell lines from patients with differing serum alkaline phosphatase concentrations display minimal differences in gene expression patterns.

Authors:  L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein
Journal:  Vet Comp Oncol       Date:  2015-02-03       Impact factor: 2.613

2.  Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.

Authors:  Laura Bongiovanni; Francesca Mazzocchetti; Daniela Malatesta; Mariarita Romanucci; Andrea Ciccarelli; Paolo Buracco; Raffaella De Maria; Chiara Palmieri; Marina Martano; Emanuela Morello; Lorella Maniscalco; Leonardo Della Salda
Journal:  BMC Vet Res       Date:  2012-06-11       Impact factor: 2.741

Review 3.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

4.  Unraveling the chaotic genomic landscape of primary and metastatic canine appendicular osteosarcoma with current sequencing technologies and bioinformatic approaches.

Authors:  Shirley Chu; Zachary L Skidmore; Jason Kunisaki; Jason R Walker; Malachi Griffith; Obi L Griffith; Jeffrey N Bryan
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

5.  Genomic instability and telomere fusion of canine osteosarcoma cells.

Authors:  Junko Maeda; Charles R Yurkon; Hiroshi Fujisawa; Masami Kaneko; Stefan C Genet; Erica J Roybal; Garrett W Rota; Ethan R Saffer; Barbara J Rose; William H Hanneman; Douglas H Thamm; Takamitsu A Kato
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

6.  Prevalence and potentially prognostic value of C-circles associated with alternative lengthening of telomeres in canine appendicular osteosarcoma.

Authors:  Ludmila Bicanova; Theresa Kreilmeier-Berger; Martin Reifinger; Klaus Holzmann; Miriam Kleiter
Journal:  Vet Comp Oncol       Date:  2020-12-08       Impact factor: 2.613

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.